Navitoclax-piperazine

SKU: orb1309354

Description

Navitoclax-piperazine, also known as ABT-263-piperazine, is a potent and selective BCL-XL inhibitor. It is widely used in oncology research, demonstrating efficacy in inducing apoptosis in cellular assays and showing activity in preclinical in vivo models of hematologic cancers.

Research Area

Cell Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 2143096-93-7
• MW: 973.63
• Purity: 99.82%
• Formula: C₄₇H₅₆ClF₃N₆O₅S₃
• SMILES: CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCNCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
• Target: Ligands for Target Protein for PROTAC,Bcl-2 Family
• Solubility: 10% DMSO+90% Corn Oil:3.3 mg/mL (3.39 mM);DMSO:250 mg/mL (256.77 mM)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ABT-263-piperazine, B-cell, Bcl-xL, Bcl-2 Family, Ligands for Target Protein for PROTAC, LigandsforTargetProteinforPROTAC, ligase, inhibit, lymphoma, Navitoclax piperazine, Navitoclaxpiperazine, Navitoclax-piperazine, Inhibitor, Target Protein-binding Moiety, VHL, ubiquitin

Compound Identifiers

PubChem CID

132020434